Structurally-modified Antibody, Immunoglobulin, Or Fragment Thereof (e.g., Chimeric, Humanized, Cdr-grafted, Mutated, Etc.) Patents (Class 424/133.1)
  • Patent number: 11407838
    Abstract: The present invention relates to compositions comprising erenumab and one or more erenumab variants, including isomerization variants, deamidation variants, acidic variants, and HMW species. Pharmaceutical formulations comprising the erenumab compositions and methods of using and characterizing the compositions are also described.
    Type: Grant
    Filed: April 1, 2019
    Date of Patent: August 9, 2022
    Assignee: AMGEN INC.
    Inventors: Kenneth Lawson, Noel Rieder, Suminda Hapuarachchi, Jose Gregorio Ramirez
  • Patent number: 11400109
    Abstract: The present invention provides, among other things, methods of formulating nucleic acid-containing nanoparticles with an enzyme to afford efficient delivery of payload to a cell or tissue of interest via subcutaneous administration. In some embodiments, the present invention provides a process in which mRNA-loaded lipid nanoparticles are co-mixed with various amounts of hyaluronidase and administered via subcutaneous administration. The resulting payload can be efficiently delivered to the liver and other organs or tissues of a treated subject.
    Type: Grant
    Filed: November 10, 2017
    Date of Patent: August 2, 2022
    Assignee: Translate Bio, Inc.
    Inventors: Shrirang Karve, Frank DeRosa, Zarna Bhavsar, Michael Heartlein
  • Patent number: 11401349
    Abstract: The present disclosure relates to a multi-specific antibody molecule comprising or consisting of three polypeptides: a) a polypeptide chain of formula (I):(Vxx)nVx-Cx-X-V1; and b) a polypeptide chain of formula (II): (Vyy)nVy-Cy c) a polypeptide of formula (III):V2 wherein Vx represents a variable domain, Vxx represents a variable domain, Cx represents a constant region, X represents a linker, V represents a variable domain, Vy represents a variable domain, Vyy represents a variable domain, Cy represents a constant region, V2 represents a variable domain, nindependently represents 0 or 1, wherein the polypeptide chain of formula (I) and the polypeptide chain of formula (II) is aligned such that the constant regions Cx and Cy are paired and the variable domains Vx and Vy are paired to form a binding domain and optionally a disulphide bond is present between V1 and V2, in particular where a disulphide bond is present.
    Type: Grant
    Filed: September 17, 2019
    Date of Patent: August 2, 2022
    Assignee: UCB Biopharma SRL
    Inventors: Emma Dave, Sam Philip Heywood, David Paul Humphreys
  • Patent number: 11401323
    Abstract: Disclosed herein are antibodies or immunogenic fragments thereof that specifically bind to Epstein-Barr virus (EBV) glycoprotein 350 (gp350) or 220 or one or more epitopes of EBV gp350 and neutralize EBV infection. Also disclosed are immunogenic peptides comprising one or more gp350 epitopes, EBV antibody-small molecule conjugates and pharmaceutical compositions comprising the antibody or an immunogenic fragment thereof, one or more epitopes of EBV gp350, one or more immunogenic peptides, or the EBV antibody-small molecule conjugate. The antibodies, epitopes, immunogenic peptides, conjugates, and pharmaceutical compositions can be used to treat or prevent EBV infections and EBV-associated conditions and diseases.
    Type: Grant
    Filed: April 27, 2018
    Date of Patent: August 2, 2022
    Assignees: CITY OF HOPE, CALIFORNIA INSTITUTE OF TECHNOLOGY
    Inventors: Javier Gordon Ogembo, Lorraine Zvichapera Mutsvunguma, Alison Evelynn Ondrus
  • Patent number: 11397184
    Abstract: Described herein are methods for selecting cancer patients for treatment with a combination therapy comprising entinostat and a second therapeutic agent. In particular, methods are provided for the examination of a non-cancer cell type, myeloid-derived suppressor cells, e.g., those which are CD14-positive and HLA-DR-(lo/negative), as a therapeutic indicator in the setting of entinostat combination therapies.
    Type: Grant
    Filed: September 2, 2016
    Date of Patent: July 26, 2022
    Assignee: SYNDAX PHARMACEUTICALS, INC.
    Inventor: Peter Ordentlich
  • Patent number: 11396550
    Abstract: The present invention relates to anti-human OX40L antibodies, new medical uses and methods.
    Type: Grant
    Filed: July 27, 2017
    Date of Patent: July 26, 2022
    Assignee: Kymab Limited
    Inventors: Jamie Campbell, Steve Holmes, Ian Kirby, Miha Kosmac
  • Patent number: 11389481
    Abstract: A population of genetically engineered immune cells (e.g., T cells), which express a chimeric antigen receptor (CAR) specific to CD19 and contain a disrupted TRAC gene, a disrupted B2M gene, or both, for use in treating a B cell malignancy.
    Type: Grant
    Filed: April 22, 2021
    Date of Patent: July 19, 2022
    Assignee: CRISPR Therapeutics AG
    Inventors: Mark Benton, Tony Ho, Demetrios Kalaitzidis, Ewelina Morawa, Jonathan Alexander Terrett
  • Patent number: 11390677
    Abstract: The present invention provides antibodies that bind to CD47 with high affinity and specificity, and their use in treatment of a cancer.
    Type: Grant
    Filed: July 3, 2019
    Date of Patent: July 19, 2022
    Assignee: TRICAN BIOTECHNOLOGY CO., LTD.
    Inventors: Huang-Tsu Chen, Jiun-Shyang Leou, Chung-Yuan Hsu, Cheng-Ke Li, Yun-Ting Wang, Li-Tsen Lin, Shiou-Ting Chen, Chen-Wei Chiang
  • Patent number: 11382974
    Abstract: Methods and pharmaceutical compositions for treatment of amyloid deposition diseases using chimeric (e.g., mouse-human) antibody are disclosed, including a method for treating amyloid deposition diseases with cardiac involvement by administering pharmaceutical compositions comprising a chimeric anti-amyloid fibril antibody. The methods herein can improve myocardial function in patients diagnosed with light chain amyloid light chain amyloidosis (ALA) having a cardiac involvement in as little as three weeks after treatment.
    Type: Grant
    Filed: June 28, 2018
    Date of Patent: July 12, 2022
    Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
    Inventor: Suzanne Lentzsch
  • Patent number: 11384143
    Abstract: The disclosure provides methods of treating inflammation without inducing immune suppression. The method comprises administering a therapeutically effective amount of an IL-6 antagonist at a dose sufficient to reduce inflammation without causing immune suppression.
    Type: Grant
    Filed: April 26, 2019
    Date of Patent: July 12, 2022
    Assignee: NOVO NORDISK A/S
    Inventors: Madhav N. Devalaraja, Michael H. Davidson, Rahul Kakkar
  • Patent number: 11377495
    Abstract: Markers of acute myeloid leukemia stem cells (AMLSC) are identified. The markers are differentially expressed in comparison with normal counterpart cells, and are useful as diagnostic and therapeutic targets.
    Type: Grant
    Filed: June 17, 2021
    Date of Patent: July 5, 2022
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Ravindra Majeti, Irving L. Weissman, Siddhartha Jaiswal, Mark P. Chao
  • Patent number: 11377485
    Abstract: Methods for making modified Fc regions of antibodies and antibody fragments, both human and humanized, and having enhanced stability and efficacy, are provided. Antibodies comprising Fc regions with core fucose residues removed, and attached to oligosaccharides comprising terminal sialyl residues, are provided. Antibodies comprising homogeneous glycosylation of Fc regions with specific oligosaccharides are provided. Fc regions conjugated with homogeneous glycoforms of monosaccharides and trisaccharides, are provided. Methods of preparing human antibodies with modified Fc using glycan engineering, are provided.
    Type: Grant
    Filed: October 2, 2018
    Date of Patent: July 5, 2022
    Assignee: ACADEMIA SINICA
    Inventors: Chi-Huey Wong, Chung-Yi Wu
  • Patent number: 11369896
    Abstract: The present disclosure relates to, inter alia, a method of quantitating an amount of an antibody molecule from a mixture comprising two or more antibody molecules, comprising separating each of the two or more antibody molecules from the mixture by hydrophobic interaction chromatography high performance liquid chromatography (HIC-HPLC) and quantitating an amount of each antibody molecule, wherein the molecular weight of each antibody molecule is within 15 kDa of any other antibody molecule in the mixture and either each antibody molecule is different from another antibody molecule in the mixture by more than about 0.25 unit on the Kyte & Doolittle hydropathy scale or each of the antibody molecules when run alone on HIC-HPLC elutes at distinct run time with little overlap from the other antibody molecules in the mixture, or both.
    Type: Grant
    Filed: October 21, 2020
    Date of Patent: June 28, 2022
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Dingjiang Liu, Lin Luo, Long Xu
  • Patent number: 11365239
    Abstract: Provided herein are modified anti-SARS-COV-2 antibodies or antigen binding fragments thereof having extended half life and optimized immune activities. Disclosed herein is also directed to pharmaceutical compositions comprising the same and a method for treating or preventing a disease in human patients that is caused by or related to the infection of SARS-COV-2.
    Type: Grant
    Filed: November 19, 2020
    Date of Patent: June 21, 2022
    Inventors: Zheng Zhang, Linqi Zhang, Lei Liu, Qi Zhang, Bin Ju, Xuanling Shi, Qing Zhu
  • Patent number: 11365264
    Abstract: Methods for diagnosing or treating immune disorders in a subject are provided. The methods are based on the detection or modulation of Refractory state Inducing Factor (RIF).
    Type: Grant
    Filed: December 22, 2014
    Date of Patent: June 21, 2022
    Assignee: INSTITUT PASTEUR
    Inventors: Jacques Theze, Thierry Rose, Florence Bugault
  • Patent number: 11365252
    Abstract: Disclosed are chimeric antigen receptor (CAR) polypeptides comprising a CD229 antigen binding domain, a transmembrane domain, and an intracellular signaling domain. Disclosed are nucleic acid sequences capable of encoding a CAR polypeptide comprising a CD229 antigen binding domain, a transmembrane domain, and an intracellular signaling domain. Also disclosed are vectors and cells comprising one or both of the CAR polypeptides and nucleic acid sequences capable of encoding CAR polypeptides. Also disclosed are methods of treating.
    Type: Grant
    Filed: July 19, 2017
    Date of Patent: June 21, 2022
    Assignee: UNIVERSITY OF UTAH RESEARCH FOUNDATION
    Inventors: Tim Luetkens, Djordje Atanackovic, Sabarinath Venniyil Radhakrishnan
  • Patent number: 11365258
    Abstract: The present disclosure relates generally to the fields of immunology and molecular biology. More specifically, provided herein are pharmaceutical combinations comprising (A) antibodies, or antigen-binding portions thereof, directed against LY75, and (B) a second anti-cancer entity; nucleic acids encoding antibody combinations; methods for preparing antibody combinations; and methods for the treatment of diseases, such as cancers mediated by LY75 expression or activity.
    Type: Grant
    Filed: March 9, 2018
    Date of Patent: June 21, 2022
    Assignee: BERLIN-CHEMIE AG
    Inventors: Monica Binaschi, Mario Bigioni, Giuseppe Merlino, Cecilia Simonelli, Francesco Bertoni, Andrea Pellacani
  • Patent number: 11366118
    Abstract: The application provides methods of diagnosis, prognosis, prophylaxis and treatment of CD30+ cancers.
    Type: Grant
    Filed: September 13, 2019
    Date of Patent: June 21, 2022
    Assignee: SEAGEN INC.
    Inventors: Tina Albertson, Maria L. Smith
  • Patent number: 11365191
    Abstract: Substituted cyclohexyl chemical entities of Formula (I): wherein Ra, G, and Rb have any of the values described herein, and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods, including metabolic and reaction kinetic studies; detection and imaging techniques; radioactive therapies; modulating and treating disorders mediated by nociceptin activity or dopamine signaling; treating neurological disorders, neurodegenerative diseases, depression, and schizophrenia; enhancing the efficiency of cognitive and motor training; and treating peripheral disorders, including renal, respiratory, gastrointestinal, liver, genitourinary, metabolic, and inflammatory disorders.
    Type: Grant
    Filed: February 26, 2019
    Date of Patent: June 21, 2022
    Assignee: Dart NeuroScience, LLC
    Inventors: Jillian Basinger Thompson, Brett C. Bookser, Scott Burley, Pablo Garcia-Reynaga, Andrew Hudson, Marco Peters, Benjamin Pratt, Aaron Thompson, Joe Tran, Lino Valdez
  • Patent number: 11365393
    Abstract: The present invention relates to novel compositions and methods for regulating an immune response in a subject. More particularly, the invention relates to specific antibodies that regulate the activity of NK cells and allow a potentiation of NK call cytotoxicity in mammalian subjects. The invention also relates to fragments and derivatives of such antibodies, as well as pharmaceutical compositions comprising the same and their uses, particularly in therapy, to increase NK cell activity or cytotoxicity in subjects.
    Type: Grant
    Filed: January 22, 2018
    Date of Patent: June 21, 2022
    Assignee: INNATE PHARMA
    Inventors: Alessandro Moretta, Mariella Della Chiesa
  • Patent number: 11365238
    Abstract: Neutralizing antibodies through recombinant protein expression were identified by mining antibody repertoires by high-throughput second generation sequencing. Sequencing across the majority of light and heavy chain variable regions of chicken immunoglobulins was performed at two immunological time points: a non-immune (naive) state and a post-hyperimmunization state. The mRNA was extracted from unsorted and unselected PBMC populations and identification of antigen-specific antibody sequences leveraged the significant disparity of abundance of an individual B cell clone in non-immune and immunized states. Through bioinformatic analysis, candidate amino acid sequences for variable heavy chain and light chains were identified. Recombinant polypeptides with the binding domains having the identified amino acid sequences for variable heavy chain and light chains were expressed and screened using immunoassays to confirm antigen-specificity.
    Type: Grant
    Filed: December 7, 2016
    Date of Patent: June 21, 2022
    Assignee: CAMAS INCORPORATED
    Inventors: Jeff Fagerlund, Bradley M. Mitteness, Connie Phillips
  • Patent number: 11357857
    Abstract: Disclosed herein are methods for improving a parameter of a protein-related process comprising providing a viscosity-reducing excipient compound selected from the group consisting of hindered amines, anionic aromatics, functionalized amino acids, oligopeptides, short-chain organic acids, and low molecular weight aliphatic polyacids, and adding a viscosity-reducing amount of the viscosity-reducing excipient compound to a carrier solution for the protein-related process, wherein the carrier solution contains a protein of interest, and carrier solutions comprising a liquid medium in which is dissolved a protein of interest, and a viscosity-reducing excipient, wherein the viscosity of the carrier solution has a lower viscosity that that of a control solution that is substantially similar to the carrier solution except for the presence of the viscosity-reducing excipient.
    Type: Grant
    Filed: February 14, 2018
    Date of Patent: June 14, 2022
    Assignee: Comera Life Sciences, Inc.
    Inventors: David S. Soane, Philip Wuthrich, Robert P. Mahoney, Mark Moody, Daniel G. Greene, Neil L. Schauer
  • Patent number: 11352423
    Abstract: The present disclosure describes a pharmaceutical formulation of an anti-CD19 antibody.
    Type: Grant
    Filed: June 27, 2017
    Date of Patent: June 7, 2022
    Assignee: MORPHOSYS AG
    Inventors: Patrick Garidel, Andreas Langer, Martin Hessling, Daniel Weinfurtner, Bodo Brocks
  • Patent number: 11352414
    Abstract: The invention relates to multimeric fusion proteins which bind to human Fc receptors. The invention also relates to therapeutic compositions comprising the proteins, and their use in the treatment of immune disorders.
    Type: Grant
    Filed: March 5, 2015
    Date of Patent: June 7, 2022
    Inventors: Farnaz Fallah-Arani, Robert Anthony Griffin, David Paul Humphreys, Shirley Jane Peters, Bryan John Smith, Paul Edward Stephens
  • Patent number: 11352434
    Abstract: Described herein are chimeric antigen receptors (CARs) targeting CD37, as well as related molecules and methods.
    Type: Grant
    Filed: March 16, 2018
    Date of Patent: June 7, 2022
    Assignee: The General Hospital Corporation
    Inventors: Marcela V. Maus, Irene Scarfo
  • Patent number: 11351253
    Abstract: The disclosure is directed to methods, treatment regimens, uses, kits and therapies for treating Generalized Pustular Psoriasis (GPP). These methods, treatment regimens, uses, kits and therapies utilize, inter cilia, administration of an IL-17 antagonist, e.g., an IL-17 antibody, such as secukinumab. Additionally disclosed are improved methods for treating plaque-type psoriasis that utilize up-titration and down-titration of the IL-17 antagonist, e.g., an IL-17 antibody, such as secukinumab, as well as modification of dose frequency. Further disclosed are methods of treating palmoplantar pustular psoriasis using the disclosed IL-17 antagonists, e.g., IL-17 antibodies, such as secukinumab.
    Type: Grant
    Filed: August 29, 2019
    Date of Patent: June 7, 2022
    Assignee: NOVARTIS AG
    Inventors: Charis Papavassilis, Oliver Sander, Tomohiro Shima, Susumu Kitamura
  • Patent number: 11344505
    Abstract: Formulations and methods for treating inflammation using pitcher plants are described herein. The pitcher plant is made into herbal preparations, such as tinctures and infused solutions. The herbal preparation of the pitcher plant can be combined with vitamins, minerals, glutathione, solutions, and other plant preparations, such as a hemp plant preparation containing cannabidiol, to make a topical formulation. Administering the formulation to a subject can reduce and treat inflammation.
    Type: Grant
    Filed: October 5, 2018
    Date of Patent: May 31, 2022
    Assignee: GOWEY RESEARCH GROUP, PLLC
    Inventor: Brandie Gowey
  • Patent number: 11345730
    Abstract: The present invention relates to a chimeric protein comprising at least one human amyloid P component and at least one fragment of an Fc region of a human antibody, the human amyloid P component and the fragment of an Fc region with which it is associated being bound to each other by means of a hinge region.
    Type: Grant
    Filed: May 11, 2018
    Date of Patent: May 31, 2022
    Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), UNIVERSITÉ DE LIMOGES
    Inventors: Christophe de Romeuf, Christophe Sirac, Jean-Claude Brouet
  • Patent number: 11337975
    Abstract: The present disclosure relates to a pharmaceutical combination comprising (a) a histone deacetylase inhibitor and (b) a CD38 inhibitor, including combined preparations and pharmaceutical compositions thereof; uses of such combination in the treatment or prevention of cancer; and methods of treating or preventing cancer in a subject comprising administering a therapeutically effective amount of such combination.
    Type: Grant
    Filed: November 22, 2017
    Date of Patent: May 24, 2022
    Assignee: Acetylon Pharmaceuticals, Inc.
    Inventors: Steven Norman Quayle, Simon Stewart Jones, Teru Hideshima, Kenneth C. Anderson
  • Patent number: 11337965
    Abstract: The present technology relates to methods for treating, preventing, and/or ameliorating kinase mutation-associated neurodegenerative diseases, including BRAFV600E-associated neurodegenerative diseases, in a subject in need thereof. In particular aspects, the present technology relates to the use of BRAF, MEK, and/or CSF-IR inhibitors to treat, prevent, and/or ameliorate kinase mutation-associated neurodegenerative diseases, including BRAFV600E-associated neurodegenerative diseases.
    Type: Grant
    Filed: August 24, 2018
    Date of Patent: May 24, 2022
    Assignee: MEMORIAL SLOAN KETTERING CANCER CENTER
    Inventors: Frederic Geissmann, Elvira Mass, Rocio Vicario
  • Patent number: 11339221
    Abstract: The present invention relates to bispecific antibody constructs that specifically bind both integrin alpha-V and integrin ?5 (e.g., ?5?1) and methods of making and using those constructs to treat cancer or other pathological conditions involving these integrins.
    Type: Grant
    Filed: October 30, 2018
    Date of Patent: May 24, 2022
    Assignee: Tufts Medical Center, Inc.
    Inventor: Paul Mathew
  • Patent number: 11339205
    Abstract: The invention relates to a Myc dominant negative mutant, called Omomyc, for use in medicine and for use in the prevention and/or treatment of cancer. The invention also refers to a fusion protein comprising Omomyc and pharmaceutical composition thereof and their use in medicine and, in particular, for treatment of cancer.
    Type: Grant
    Filed: June 6, 2019
    Date of Patent: May 24, 2022
    Assignees: FUNDACIÓ PRIVADA INSTITUT D'INVESTIGACIÓ, ONCOLÓGICA DE VALL HEBRON
    Inventors: Laura Soucek, Marie-Eve Beaulieu
  • Patent number: 11332544
    Abstract: Genetically engineered antibodies containing non-native N-glycosylated sites, preparation of the antibodies in yeast and fungi, site-specific conjugation of drugs to these antibodies, and methods of treatment utilizing these antibodies are described herein.
    Type: Grant
    Filed: April 21, 2017
    Date of Patent: May 17, 2022
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Robert Davidson, Bing Gong
  • Patent number: 11332537
    Abstract: Provided herein are anti-CD27 and anti-PD-L1 antibodies, and binding domains thereof, as well as bispecific constructs and anti-CD27 binding domain linked to an anti-PD-L1 binding domain. Also provided herein are methods of stimulating T cell activity, methods of inducing or enhancing an immune response, and methods of treating a disease or condition by administering the bispecific constructs, antibodies, or antigen binding fragments thereof, or compositions described herein to a patient in need thereof.
    Type: Grant
    Filed: August 18, 2021
    Date of Patent: May 17, 2022
    Assignee: Celldex Therapeutics, Inc.
    Inventors: Tibor Keler, Joel Goldstein, Laura A. Vitale, Lizhen He
  • Patent number: 11332542
    Abstract: Disclosed are antibodies which bind human and Macaca fascicularis CEACAM5 proteins, as well as isolated nucleic acids, vectors and host cells comprising a sequence encoding the antibodies. Also disclosed are immunoconjugates comprising the antibodies conjugated or linked to a growth-inhibitory agent, and pharmaceutical compositions comprising the antibodies or immunoconjugates of the invention. The antibodies or immunoconjugates are used for the treatment of cancer or for diagnostic purposes.
    Type: Grant
    Filed: September 3, 2019
    Date of Patent: May 17, 2022
    Assignee: SANOFI
    Inventors: Pierre-Francois Berne, Francis Blanche, Hervé Bouchard, Béatrice Cameron, Tarik Dabdoubi, Stéphanie Decary, Paul Ferrari, Alexey Rak
  • Patent number: 11331372
    Abstract: The present invention provides methods for the identification of patients with an inflammatory or autoimmune disease that demonstrate an inadequate response to treatment with a multi-Fc therapeutic, and the determination of an optimal dose of a multi-Fc therapeutic for said patient based on the patient's circulating levels of inactivated C3b (iC3b) and/or additional complement components that may be employed as a surrogate for iC3b based on an analogous response to multi-Fc therapeutics. The present invention further provides for improvements in the use of such multi-Fc therapeutics in the treatment of autoimmune and inflammatory diseases.
    Type: Grant
    Filed: December 8, 2017
    Date of Patent: May 17, 2022
    Assignee: GLIKNIK INC.
    Inventors: David S. Block, Henrik Olsen
  • Patent number: 11318163
    Abstract: Compositions disclosed herein, and methods of use thereof included those for treating or preventing sepsis in a subject in need, including methods of extending of the survival of a subject suffering from sepsis, and reduction of organ dysfunction or failure due to sepsis. Methods of treating or preventing sepsis in a subject in need includes administering compositions comprising early apoptotic cells or early apoptotic cell supernatants. Compositions and methods of use thereof may reduce the negative proinflammatory effect accompanying sepsis. Further, anti-inflammatory cytokine release may be reduced. In certain instances, compositions may include additional agents.
    Type: Grant
    Filed: November 4, 2019
    Date of Patent: May 3, 2022
    Assignee: ENLIVEX THERAPEUTICS LTD
    Inventors: Shai Novik, Dror Mevorach
  • Patent number: 11319378
    Abstract: Provided are an anti-PD-1/anti-HER2 natural antibody structural heterodimeric bispecific antibody and a method of preparing the same. Specifically, provided are a highly stable anti-PD-1/anti-HER2 heterodimeric bispecific antibody having characteristics of a natural IgG and having no mismatched heavy chain and light chain, and a method of preparing the same. The bispecific antibody may bind to both of two kinds of target molecules, and thus may be more effective in treating complex diseases.
    Type: Grant
    Filed: November 16, 2017
    Date of Patent: May 3, 2022
    Assignee: BEIJING HANMI PHARMACEUTICAL CO., LTD.
    Inventors: Jiawang Liu, Nanmeng Song, Yaping Yang, Maengsup Kim
  • Patent number: 11319383
    Abstract: The present invention relates to compositions and methods for antibody-mediated therapy. In particular, provided herein are engineered immunoglobulins with altered half-life.
    Type: Grant
    Filed: March 14, 2017
    Date of Patent: May 3, 2022
    Assignee: Universitetet | Oslo
    Inventors: Jan Terje Andersen, Stian Foss, Inger Sandlie
  • Patent number: 11318138
    Abstract: Described herein are methods for treating B cell proliferative disorders, in an individual in need thereof. The methods include administering to an individual in need thereof a Btk inhibitor (e.g., ibrutinib), in combination with a CDK4 inhibitor (e.g., palbociclib).
    Type: Grant
    Filed: April 26, 2019
    Date of Patent: May 3, 2022
    Assignee: Cornell University
    Inventors: Selina Chen-Kiang, Maurizio Di Liberto
  • Patent number: 11312770
    Abstract: The present invention is directed to bispecific, heterodimeric checkpoint antibodies.
    Type: Grant
    Filed: November 8, 2018
    Date of Patent: April 26, 2022
    Assignee: Xencor, Inc.
    Inventors: Matthew Bernett, Gregory Moore, John Desjarlais, Michael Hedvat, Christine Bonzon, Alex Nisthal, Umesh Muchhal
  • Patent number: 11311575
    Abstract: The present invention relates to methods for developing engineered T-cells for immunotherapy and more specifically to methods for modifying T-cells by inactivating at immune checkpoint genes, preferably at least two selected from different pathways, to increase T-cell immune activity. This method involves the use of specific rare cutting endonucleases, in particular TALE-nucleases (TAL effector endonuclease) and polynucleotides encoding such polypeptides, to precisely target a selection of key genes in T-cells, which are available from donors or from culture of primary cells. The invention opens the way to highly efficient adoptive immunotherapy strategies for treating cancer and viral infections.
    Type: Grant
    Filed: May 13, 2014
    Date of Patent: April 26, 2022
    Assignee: CELLECTIS
    Inventors: Roman Galetto, Agnes Gouble, Stephanie Grosse, Cécile Schiffer-Mannioui, Laurent Poirot, Andrew Scharenberg, Julianne Smith
  • Patent number: 11312763
    Abstract: The invention is directed to a short term induction treatment with anti-N3pGlu A? antibodies of a disease characterized by deposition of A? in the brain, that include Alzheimer's disease (AD), Down's syndrome, and cerebral amyloid angiopathy (CAA). In certain embodiments, patients are administered an induction dose of 10 to 60 mg/kg of an anti-N3pGlu A? antibody for a period of 6 months or less.
    Type: Grant
    Filed: June 23, 2017
    Date of Patent: April 26, 2022
    Assignee: Eli Lilly and Company
    Inventors: Ronald Bradley Demattos, Michael Carl Irizarry
  • Patent number: 11305005
    Abstract: This application relates to the field of prevention of pneumonia by administration of a high-dose influenza vaccine.
    Type: Grant
    Filed: June 23, 2016
    Date of Patent: April 19, 2022
    Assignee: SANOFI PASTEUR INC.
    Inventors: Carlos DiazGranados, Andrew Dunning
  • Patent number: 11304976
    Abstract: Compositions disclosed herein, and methods of use thereof included those for treating or preventing sepsis in a subject in need, including methods of extending of the survival of a subject suffering from sepsis, and reduction of organ dysfunction or failure due to sepsis. Methods of treating or preventing sepsis in a subject in need includes administering compositions comprising early apoptotic cells or early apoptotic cell supernatants. Compositions and methods of use thereof may reduce the negative proinflammatory effect accompanying sepsis. In certain instances, compositions may include additional agents.
    Type: Grant
    Filed: November 19, 2018
    Date of Patent: April 19, 2022
    Assignee: ENLIVEX THERAPEUTICS LTD
    Inventors: Shai Novik, Dror Mevorach
  • Patent number: 11305012
    Abstract: Provided herein are antibodies and antigen binding fragments thereof that bind the extracellular domain of the HER3 receptor and inhibit various HER3 receptor related functions via ligand-dependent and/or ligand-independent mechanisms. Also provided are compositions with increased half-life, as well as compositions and methods for diagnosing and treating diseases associated with HER3 mediated signal transduction.
    Type: Grant
    Filed: September 23, 2014
    Date of Patent: April 19, 2022
    Assignee: MedImmune, LLC
    Inventors: Partha S. Chowdhury, David Tice, Zhan Xiao, Philipp Steiner, Krista Kinneer, Marlon Rebelatto, Andrew Pierce
  • Patent number: 11306360
    Abstract: The present application mainly relates to specific methods for inferring activity of a cellular signaling pathway in tissue and/or cells of a medical subject based at least on expression levels of one or more target gene(s) of the cellular signaling pathway measured in an extracted sample of the tissue and/or cells of the medical subject, an apparatus comprising a digital compressor configured to perform such methods and a non-transitory storage medium storing instructions that are executable by a digital processing device to perform such methods.
    Type: Grant
    Filed: December 18, 2013
    Date of Patent: April 19, 2022
    Assignee: KONINKLIJKE PHILIPS N.V.
    Inventors: Hendrik Jan Van Ooijen, Wilhelmus Franciscus Johannes Verhaegh, Paul Arnold Van De Wiel
  • Patent number: 11299552
    Abstract: The present disclosure generally relates to chimeric antigen receptors, more specifically to chimeric antigen receptor compositions and methods for use of the same. The present disclosure also provides for nucleic acid molecules and expression vectors for making and using the chimeric antigen receptors and for co-receptor signaling using such chimeric antigen receptors. The present disclosure also provides methods of treatment using such compositions. The chimeric antigen receptors of the present disclosure interact with the endogenous T-cell receptor complex enabling physiological control of signaling and T-cell response and can be combined with ligands such as co-stimulatory ligands for further controlling and influencing T-cell activation and response.
    Type: Grant
    Filed: November 1, 2018
    Date of Patent: April 12, 2022
    Assignee: University of Kansas
    Inventors: Thomas Yankee, John Szarejko
  • Patent number: 11298354
    Abstract: The disclosure relates to pharmaceutical combinations comprising an HDAC6 selective inhibitor and a BET inhibitor for the treatment of cancer in a subject in need thereof. Also provided herein are methods for treating cancer in a subject in need thereof, comprising administering to the subject an effective amount of an HDAC6 selective inhibitor and a BET inhibitor.
    Type: Grant
    Filed: June 9, 2017
    Date of Patent: April 12, 2022
    Assignees: DANA-FARBER CANCER INSTITUTE, INC., ACETYLON PHARMACEUTICALS, INC.
    Inventors: Kwok-kin Wong, Yan Liu, Dennis O. Adeegbe, Steven Norman Quayle
  • Patent number: 11299551
    Abstract: Provided are anti-CD19 and anti-CD38 common light chain bispecific antibodies. The anti-CD19 and anti-CD38 bispecific antibodies described herein are useful in methods for treating a cancer or a tumor.
    Type: Grant
    Filed: April 13, 2021
    Date of Patent: April 12, 2022
    Assignee: Biograph 55, Inc.
    Inventors: Leonard Presta, Paul Tumeh, Nils Lonberg, Omar Duramad